Phase 3 Sugar Controller Reduces Insulin, Glucose Response

KEARNY, N.J.Findings from pilot and clinical studies showed Phase 3 Sugar Controller, a patent-pending, proprietary combination of a specific form of L-arabinose and a patented form of chromium, significantly reduced blood glucose and insulin responses to sucrose challenges, according to Pharmachem Laboratories, developer of the ingredient.

The pilot study of 20 healthy, non-diabetic subjects showed taking Phase 3 Sugar Controller led to an average reduction in glucose of 31 percent, and an average reduction in insulin of 32 percent when presented with a 70-g sucrose challenge. In the two-phase clinical trial of 50 healthy non-diabetic adults, subjects taking Phase 3 Sugar Controller had an average reduction in glucose of 24.3 percent, and an average reduction in insulin of 28.2 percent when faced with the same sucrose challenge.

"The overall conclusion from these studies is supplementation with Phase 3 Sugar Controller can lead to a significant reduction of blood glucose and insulin responses to simple sugar without adverse side effects," said lead researcher Gilbert R. Kaats, Ph.D., CEO of Integrative Health Technologies, San Antonio, Texas.

Mitch Skop, Pharmachems senior director of new product development, added, With conditions such as obesity, diabetes and metabolic syndrome continuing to skyrocket in the U.S. population, supplements and functional foods/beverages containing Phase 3 Sugar Controller make sense. It is one effective and safe tool in a positive lifestyle that helps control and manage healthy blood sugar and insulin responses. If the average American consumer eats or drinks 100 pounds of sugar per year, supplementation with Phase 3 Sugar Controller could reduce the impact by more than 25 pounds per year.  Consider that over a lifetime of 10, 20, 30 years, and it could have a profound and clinically meaningful effect on health and wellness."

The safety profile of Phase 3 was shown in these studies to be attractive. There were no adverse effects reported, nor were there any significant changes in the 44 blood chemistries, body composition or self-reported quality of life measures taken after Phase 3 Sugar Controller was used as recommended for 30 days. 

The studies were included in a paper entitled, "The Effects of a Patent Pending Combination of L-Arabinose and a Patented Chromium Supplement (LA/Cr) on Capillary Glucose and Serum Insulin Levels After Sucrose Challenges," which has been submitted for publication.